Yeah, I mean, and the United States.

Yeah, absolutely.

And this is like not a new, this is not a new issue.

Like, Trips seems to supersede a lot of laws even in the EU that try and regulate competition

and development among pharmaceutical companies.

And in 2009, there was this big report put out by the European Commission called, it was a

pharmaceutical sector inquiry report that

really basically said that a lot of these practices were absolutely illegal under EU competition

laws. That was over, I mean, that was a lot, that was over 10 years ago and not a single

development has come out of that huge report that everybody was saying. This is like,

you know, a big turning point moment. Like, you know, Farma is going to be finally held accountable

for its monopolies. And yeah, absolutely did not happen. Well, I think what happened probably is,

you know, Farmer is very good, like all operations of capital, really, but Farmer in particular

is very good. I think at recognizing when, recognizing when there's a shot across their bow and then

having, I mean, the, you know, the example that you gave is from 2009. They have plenty of time

to reorient their ship to sort of try to turn things around from a PR or a social reproductive

perspective. I think another good example of that, frankly, is not the last time, I think.

But like in 2012, there was a trips waiver granted for domestic production in India also of a,

of a cancer drug made by Bayer.

And the like ripple effects of that if you will are pretty

indicative I think of what I'm talking about in terms of being able to kind of recognize when

there's a shot across there about because just a year or two later the Bayer CEO the then

...